Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IO-Pc 4
- Development stage
- Preclinical
- Lead developer
- Ocean NanoTech
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
IO-Pc 4 is a nanoparticle-based theranostic agent designed for photodynamic therapy (PDT) and magnetic resonance imaging (MRI). It consists of the second-generation photosensitizer Pc 4 (a silicon phthalocyanine) encapsulated within or conjugated to iron oxide (IO) nanoparticles. The iron oxide core provides magnetic properties that allow the formulation to serve as a contrast agent for MRI-guided localization and monitoring. Upon activation by specific wavelengths of light, the Pc 4 payload generates reactive oxygen species, primarily singlet oxygen, which induce apoptosis and necrosis in tumor cells. This nanoparticle delivery system is intended to improve the solubility and tumor accumulation of the hydrophobic Pc 4 molecule while reducing the light-associated systemic toxicity often associated with conventional PDT drugs.
- Other names
- iron oxide-Pc 4 nanoparticlePc 4-loaded iron oxide nanoparticlePc4-loaded iron oxide nanoparticlePc-4-loaded iron oxide nanoparticle
Beyond the preview
Go deeper on IO-Pc 4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IO-Pc 4.